Jieduquyuziyin Prescription-Treated Rat Serum Suppresses Activation of Peritoneal Macrophages in MRL/Lpr Lupus Mice by Inhibiting IRAK1 Signaling Pathway.
Journal
Evidence-based complementary and alternative medicine : eCAM
ISSN: 1741-427X
Titre abrégé: Evid Based Complement Alternat Med
Pays: United States
ID NLM: 101215021
Informations de publication
Date de publication:
2019
2019
Historique:
received:
27
07
2019
revised:
11
09
2019
accepted:
27
09
2019
entrez:
30
11
2019
pubmed:
30
11
2019
medline:
30
11
2019
Statut:
epublish
Résumé
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease, and Jieduquyuziyin prescription (JP) is a traditional Chinese medicine (TCM) formula that has been testified to be effective for SLE treatment as an approved hospital prescription for many years in China. However, its mechanism of action in the treatment of this disease is largely unknown. The purpose of this study was to determine whether JP-treated rat serum can inhibit the activation of peritoneal macrophages in MRL/lpr mice by downregulating the IRAK1 signaling pathway, thereby achieving the effect of improving SLE. The JP-treated rat serum was prepared, and the peritoneal macrophages of MRL/lpr lupus mice were isolated in vitro, and the effect of JP on cell viability was detected by the CCK8 method. After LPS induction and shRNA lentiviral transfection, the effect of JP on the expression of IRAK1 in cells was detected by immunofluorescence staining. The content of TNF-
Identifiants
pubmed: 31781262
doi: 10.1155/2019/2357217
pmc: PMC6875022
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2357217Informations de copyright
Copyright © 2019 Lina Ji et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest regarding the publication of this paper.
Références
J Biol Chem. 2015 Jan 30;290(5):2831-41
pubmed: 25505246
Nat Rev Rheumatol. 2013 Nov;9(11):687-94
pubmed: 23838616
Arthritis Rheum. 2007 Dec;56(12):4164-73
pubmed: 18050247
Biochem Pharmacol. 2010 Dec 15;80(12):1981-91
pubmed: 20599782
Clin Rheumatol. 2013 Jul;32(7):1071-3
pubmed: 23456414
PLoS One. 2014 Feb 05;9(2):e88223
pubmed: 24505438
Evid Based Complement Alternat Med. 2018 Oct 8;2018:2734581
pubmed: 30402118
In Vitro Cell Dev Biol Anim. 2018 Dec;54(10):692-704
pubmed: 30367366
Front Immunol. 2016 Feb 02;7:22
pubmed: 26870038
J Exp Med. 2003 Oct 6;198(7):1043-55
pubmed: 14517278
J Tradit Chin Med. 2011 Sep;31(3):163-8
pubmed: 21977854
Microb Pathog. 2018 Nov;124:223-229
pubmed: 30149133
Cell Signal. 2008 Feb;20(2):269-76
pubmed: 17890055
Shock. 2002 Aug;18(2):99-106
pubmed: 12166787
J Immunol. 2010 Jun 1;184(11):6465-78
pubmed: 20427764
Science. 1996 Feb 23;271(5252):1128-31
pubmed: 8599092
J Autoimmun. 2015 Feb;57:42-52
pubmed: 25554644
Nat Rev Rheumatol. 2013 Apr;9(4):197
pubmed: 23439034
Inflamm Res. 2013 Jun;62(6):555-60
pubmed: 23435933
J Ethnopharmacol. 2018 May 10;217:220-227
pubmed: 29476961
Hum Mol Genet. 2009 Feb 1;18(3):482-96
pubmed: 18996917
Clin Rev Allergy Immunol. 2013 Jun;44(3):229-41
pubmed: 22826112
Z Rheumatol. 2009 May;68(3):205-8, 210-13
pubmed: 19399510
PLoS One. 2014 Jun 11;9(6):e99053
pubmed: 24918924
J Clin Immunol. 2013 Jul;33(5):925-37
pubmed: 23479181
J Nat Med. 2015 Jul;69(3):349-57
pubmed: 25821132
Curr Opin Rheumatol. 2017 Sep;29(5):442-449
pubmed: 28639951
PLoS One. 2015 Feb 17;10(2):e0118462
pubmed: 25689512